Move Over Roivant, Nuvation: EQRx Reveals Biggest Biopharma SPAC Merger This Year

Deal Gives Developer Of Low-Cost Drugs $1.8bn In New Cash

 
• By Mandy Jackson
Dollar sign made out of white pills on blue background
Soon-to-be CEO says EQRx's low-cost drug business model requires big upfront investment • Source: Alamy

More from Deals

More from Business